Overcoming challenges within the supply of nucleic acid therapeutics


Credit: WIREs Nanomedicine and Nanobiotechnology (2022). DOI: 10.1002/wnan.1809

Nucleic acid therapies involving DNA or RNA have important potential to deal with genetic issues, infectious illnesses, and most cancers; nevertheless, analysis means that lower than 1% of injected nucleic acid doses attain goal cells in an lively type. An article in WIREs Nanomedicine and Nanobiotechnology highlights two of the foremost limitations to this therapeutic technique, and the way they is likely to be overcome.

Delivery to the goal cell and transport to the sub-cellular compartment the place the nucleic acids are therapeutically lively symbolize probably the most important challenges to handle. The authors discover how nanoparticle supply techniques may be modified with concentrating on molecules to extend accumulation in particular cells, and the way the composition of the nanoparticle may be engineered to control or disrupt mobile membranes and facilitate supply to the optimum sub-cellular compartments.
“Controlling the sub-cellular supply of DNA and RNA is the following main frontier for biotherapeutics. If we are able to overcome these limitations, DNA and RNA expertise has the potential to revolutionize the remedy of a spread of illnesses,” stated corresponding creator Angus P.R. Johnston, Ph.D., of Monash University, in Australia.

More info:
Lara M. Mollé et al, Nanoparticles for vaccine and gene remedy: Overcoming the limitations to nucleic acid supply, WIREs Nanomedicine and Nanobiotechnology (2022). DOI: 10.1002/wnan.1809

Citation:
Overcoming challenges within the supply of nucleic acid therapeutics (2022, November 23)
retrieved 23 November 2022
from https://phys.org/information/2022-11-delivery-nucleic-acid-therapeutics.html

This doc is topic to copyright. Apart from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

Exit mobile version